BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 33206129)

  • 1. Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction.
    Segar MW; Patel RB; Patel KV; Fudim M; DeVore AD; Martens P; Hedayati SS; Grodin JL; Tang WHW; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):68-77. PubMed ID: 33206129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of blood urea nitrogen/creatinine ratio in chronic HFpEF.
    Zhen Z; Liang W; Tan W; Dong B; Wu Y; Liu C; Xue R
    Eur J Clin Invest; 2022 Jul; 52(7):e13761. PubMed ID: 35199851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
    Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
    JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure visit-to-visit variability and outcomes in patients with heart failure with preserved ejection fraction.
    Zhang Q; Zhou B; Ma Y; Hu Y; Li X; Cong H
    ESC Heart Fail; 2021 Oct; 8(5):3984-3996. PubMed ID: 34405581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
    Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
    Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
    Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
    JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; O'Meara E; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Fang JC; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2018 Nov; 11(11):e005288. PubMed ID: 30571191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.
    Pokharel Y; Khariton Y; Tang Y; Nassif ME; Chan PS; Arnold SV; Jones PG; Spertus JA
    JAMA Cardiol; 2017 Dec; 2(12):1315-1321. PubMed ID: 29094152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial.
    Vaduganathan M; Claggett BL; Chatterjee NA; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Hegde SM; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):653-661. PubMed ID: 29501806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
    Joseph J; Claggett BC; Anand IS; Fleg JL; Huynh T; Desai AS; Solomon SD; O'Meara E; Mckinlay S; Pitt B; Pfeffer MA; Lewis EF
    JACC Heart Fail; 2016 Jun; 4(6):477-86. PubMed ID: 27039126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
    Rahimi G; Tecson KM; Elsaid O; McCullough PA
    Am J Cardiol; 2021 Mar; 142():91-96. PubMed ID: 33279481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction.
    Unger ED; Dubin RF; Deo R; Daruwalla V; Friedman JL; Medina C; Beussink L; Freed BH; Shah SJ
    Eur J Heart Fail; 2016 Jan; 18(1):103-12. PubMed ID: 26635076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
    Wei FF; Zhou Y; Wu Y; Chen X; He J; Dong Y; Staessen JA; Liu C
    Hypertens Res; 2023 Feb; 46(2):475-484. PubMed ID: 36380201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.